EuMentis Therapeutics
Newton, US · Founded 2019 · Delaware corporation · 7 employees on LinkedIn · 2 known investors
EuMentis Therapeutics develops therapies for neuropsychiatric disorders, targeting selective CNS circuits in the brain. Its lead product, EM-221, is a PDE10A inhibitor in development for schizophrenia and Parkinson's levodopa-induced dyskinesia, with a pipeline addressing conditions such as Alzheimer's-related agitation, treatment-resistant depression, bipolar disorder, and Tourette's.
Founders & leadership
AP
Andrew PearlmanNamed on SEC filing
RM
Randall MarshallNamed on SEC filing
MT
Mark TepperNamed on SEC filing
JL
James LarrickNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$11.3M disclosed across 4 rounds · 2018–2023
▶$765KraisedJun 2024 · 11 investors · PharmaceuticalsRule 506(b)
▶$765KraisedJun 2024 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Maryann BrylaDirector
- James LarrickDirector
- Randall MarshallExecutive Officer
- Kim PatrickDirector
- Mark TepperExecutive Officer, Director
- Andrew PearlmanDirector
- Offering amount
- $2M
- Amount sold
- $765K
- Minimum investment
- $20K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$4MraisedMar 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$4MraisedMar 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- mark TepperExecutive Officer, Director
- Kim PatrickDirector
- Randall MarshallExecutive Officer
- Maryann BrylaDirector
- Andrew PearlmanDirector
- James LarrickDirector
- Offering amount
- $20M
- Amount sold
- $4M
- Minimum investment
- $100K
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$5MraisedApr 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$5MraisedApr 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Randall MarshallExecutive Officer
- Mark TepperExecutive Officer, Director
- Maryann BrylaDirector
- James LarrickDirector
- Amar KapurDirector
- Andrew PearlmanDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Minimum investment
- $5M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.5MraisedSep 2020 · 25 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedSep 2020 · 25 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew PearlmanDirector
- Randall MarshallExecutive Officer
- Mark TepperExecutive Officer, Director
- James LarrickDirector
- Offering amount
- $3.3M
- Amount sold
- $1.5M
- Minimum investment
- $25K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does EuMentis Therapeutics do?
- EuMentis Therapeutics develops therapies for neuropsychiatric disorders, targeting selective CNS circuits in the brain. Its lead product, EM-221, is a PDE10A inhibitor in development for schizophrenia and Parkinson's levodopa-induced dyskinesia, with a pipeline addressing conditions such as Alzheimer's-related agitation, treatment-resistant depression, bipolar disorder, and Tourette's.
- Who are EuMentis Therapeutics's investors?
- EuMentis Therapeutics's investors include Joyance Partners, Social Starts.
- How much funding has EuMentis Therapeutics raised?
- EuMentis Therapeutics has disclosed $11.3M raised across 4 rounds.
- Where is EuMentis Therapeutics headquartered?
- EuMentis Therapeutics is headquartered in Newton, US.